Evidence map›Paper›PMID 41361444›Full record

ArticleJournal of translational medicine2025

Multi-modal integration of histopathology and transcriptomics reveals STAB1

Zhanhao Chang, Chongli Zhong, Shuo Xu, Yuyang Zhang, Xingqi Guo, Jielin Yu, Zitong Xu, Shukun Han, Bing Han, Chao Lv and 1 more

Abstract read
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The CSF1Frontiers in immunology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Zhanhao ChangDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.
Chongli ZhongDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.
Shuo XuDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.
Yuyang ZhangDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.
Xingqi GuoDepartment of General Surgery, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Cancer Hospital of Dalian University of Technology, Shenyang, Liaoning, 110042, China.
Jielin YuDepartment of Pathology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.
Zitong XuDepartment of Pathology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.
Shukun HanDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.
Bing HanDepartment of Gastroenterology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, 110001, China.
Chao LvDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China.
Yu TianDepartment of General Surgery, Shengjing Hospital of China Medical University, Shenyang, Liaoning, 110004, China. yu.tian@cmu.edu.cn.ORCID 0000-0002-2378-1220

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColon adenocarcinoma (COAD) has a limited response to immunotherapy due to its immunologically “cold” tumor microenvironment (TME). Efferocytosis is an important process that regulates the TME, but its mechanism and clinical significance in COAD are unclear.

methodsWe integrated histopathological images, transcriptomic profiles, and clinical data from 387 COAD patients. Image features were extracted using ResNet50 and CellProfiler, followed by construction of a multimodal machine learning model to evaluate prognostic risk. We further combined bulk RNA-seq, single-cell RNA-seq, and spatial transcriptomics to comprehensively characterize efferocytosis-associated immune cell subsets and signaling pathways.

resultsThe efferocytosis-based risk model demonstrated strong prognostic performance across multiple time points and remained independent of conventional clinical indicators. Mechanistically, we identified a subset of STAB1+ tumor-associated macrophages (TAMs) enriched in COAD tumors, exhibiting enhanced efferocytosis activity, M2-like polarization, and mTORC1 signaling activation. In vitro, STAB1 expression was essential for IL-4-induced M2 polarization, and its inhibition attenuated the formation of immunosuppressive TAMs. Single-cell and spatial transcriptomic analyses revealed that this macrophage population was transcriptionally distinct and increased in abundance following neoadjuvant therapy.

conclusionThis study establishes a multimodal prognostic system that integrates histopathological imaging with molecular profiling, and for the first time reveals the pivotal role of STAB1+ TAMs in orchestrating the immunosuppressive TME via efferocytosis and mTORC1 activation. Our findings provide both a clinically applicable risk assessment tool and a potential therapeutic target. Targeting STAB1 may broaden the benefit of immunotherapy for COAD patients with limited responses to immune checkpoint blockade.

Indexed as

AdenocarcinomaColonic NeoplasmsEfferocytosisGene Expression ProfilingMacrophagesTranscriptomeTumor-Associated MacrophagesGene Expression Regulation, NeoplasticHumansPrognosisSignal TransductionSpatial TranscriptomicsTumor MicroenvironmentColon adenocarcinomaDeep learningEfferocytosisHistopathologySTAB1Tumor-associated macrophages

Identifiers

PMID41361444
PMCPMC12683853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.